Tepotinib in METex14 skipping alteration NSCLC

Tepotinib in METex14 skipping alteration NSCLC

User Photo
VJOncology

2 years
145 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Enriqueta Felip, MD, PhD, of Vall dHebron University Hospital, Barcelona, Spain, discusses the VISION trial (NCT02864992) of tepotinib for non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations. Dr Felip covers the rationale behind the use of this drug, as well as the cohort and promising results of the study. This interview was recorded at the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL.
Up Next Autoplay